Chicago Partners Investment Group LLC Invests $70,000 in ImmunityBio, Inc. $IBRX

Chicago Partners Investment Group LLC purchased a new stake in shares of ImmunityBio, Inc. (NASDAQ:IBRX) in the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm purchased 26,583 shares of the company’s stock, valued at approximately $70,000.

Other institutional investors and hedge funds also recently modified their holdings of the company. Financial Enhancement Group LLC purchased a new stake in shares of ImmunityBio during the second quarter valued at approximately $28,000. Slow Capital Inc. purchased a new stake in shares of ImmunityBio during the first quarter valued at approximately $30,000. Compound Planning Inc. purchased a new stake in shares of ImmunityBio during the first quarter valued at approximately $30,000. Vigilare Wealth Management purchased a new stake in shares of ImmunityBio during the second quarter valued at approximately $31,000. Finally, Xponance Inc. purchased a new stake in shares of ImmunityBio during the first quarter valued at approximately $33,000. 8.58% of the stock is owned by hedge funds and other institutional investors.

ImmunityBio Price Performance

ImmunityBio stock opened at $2.47 on Friday. ImmunityBio, Inc. has a one year low of $1.83 and a one year high of $7.48. The business has a fifty day moving average price of $2.48 and a 200-day moving average price of $2.60. The firm has a market capitalization of $2.43 billion, a P/E ratio of -5.15 and a beta of 0.27.

ImmunityBio (NASDAQ:IBRX) last posted its quarterly earnings results on Tuesday, August 5th. The company reported ($0.10) EPS for the quarter, hitting analysts’ consensus estimates of ($0.10). The company had revenue of $26.43 million during the quarter, compared to the consensus estimate of $21.95 million. Sell-side analysts expect that ImmunityBio, Inc. will post -0.92 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of analysts recently commented on the company. HC Wainwright reaffirmed a “buy” rating and set a $8.00 price target on shares of ImmunityBio in a research report on Wednesday, September 10th. D. Boral Capital reaffirmed a “buy” rating and set a $24.00 price target on shares of ImmunityBio in a research report on Monday, September 8th. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of ImmunityBio in a research report on Tuesday, October 14th. Four analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $10.75.

ImmunityBio Profile

ImmunityBio, Inc, a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies.